Concepedia

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial

Kris M. Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Armin Ghobadi,

The Lancet Oncology · 2024 · 82 citations · 15 references

References

15

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

Madan Jagasia, Hildegard Greinix, Mukta Arora et al. · Biology of Blood and Marrow Transplantation · 2014 · 5.4K citations · Full text

Life Sciences, Immunology, Immunopathology +9

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

New England Journal of Medicine · 1993 · 5K citations · Full text

Medicine, Oncology, Chemotherapy +15

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

Tanzina Haque, Gwen Wilkie, Marie M. Jones et al. · Blood · 2007 · 644 citations

Life Sciences, Hematology, Immunology +15

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond et al. · The Lancet Oncology · 2011 · 386 citations

Medicine, Immunology, Oncology +9

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

Tanzina Haque, Gwen Wilkie, Clare Taylor et al. · The Lancet · 2002 · 365 citations

Life Sciences, Hematology, Immunology +14